Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
[Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
[fabry disease]
Anderson-
Fabry
disease
is
an
X-
linked
lysosomal
storage
disorder
resulting
from
the
deficiency
of
the
hydrolytic
enzyme
alpha
galactosidase
A
,
with
consequent
accumulation
of
globotrioasoyl
ceramide
in
cells
and
tissues
of
the
body
,
resulting
in
a
multi-system
pathology
including
end
organ
failure
.
In
the
classical
phenotype
,
cardiac
failure
,
renal
failure
and
stroke
result
and
a
reduced
median
life
expectancy
ensues
.
The
current
causal
treatment
for
Fabry
disease
is
enzyme
replacement
therapy
(
ERT
)
.
Two
different
products
,
Replagal
(
agalsidase
alfa
)
and
Fabrazyme
(
agalsidase
beta
)
,
have
been
commercially
available
in
Europe
for
almost
10
years
and
they
are
both
indicated
for
long
-term
treatment
.
In
fact
,
clinical
trials
,
observational
studies
and
registry
data
have
provided
abundant
evidence
for
the
safety
and
efficacy
of
ERT
in
improving
symptoms
of
pain
,
gastrointestinal
disorder
,
hypohidrosis
,
left
ventricular
mass
index
,
glomerular
filtration
rate
and
quality
of
life
.
Few
data
are
available
on
either
comparison
of
the
two
treatments
or
the
clinical
course
of
the
disease
.
This
article
reviews
the
published
evidence
for
the
clinical
efficacy
of
the
two
available
enzyme
preparations
.
Diseases
Validation
Diseases presenting
"with consequent accumulation of globotrioasoyl ceramide in cells and tissues of the body"
symptom
fabry disease
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom